{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bacillus+Calmette-Guerin+%28BCG%29&page=2", "query": { "intervention": "Bacillus Calmette-Guerin (BCG)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 153, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bacillus+Calmette-Guerin+%28BCG%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bacillus+Calmette-Guerin+%28BCG%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T07:28:33.890Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02324582", "title": "MK-3475/BCG in High Risk Superficial Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Intravenous MK-3475/ Intravesical BCG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Southern Illinois University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2015-06", "completion_date": "2023-03-27", "has_results": true, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-10-09T07:28:33.890Z", "location_count": 3, "location_summary": "Springfield, Illinois • Detroit, Michigan", "locations": [ { "city": "Springfield", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02324582" }, { "nct_id": "NCT02202772", "title": "Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urothelial Carcinoma of the Urinary Bladder" ], "interventions": [ { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Guarionex J. Decastro", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2014-12-01", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-10-09T07:28:33.890Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02202772" }, { "nct_id": "NCT03636256", "title": "Evaluation of NanoDoce® in Participants With Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer", "Urothelial Carcinoma", "Urinary Bladder Neoplasm", "Urinary Bladder Cancer", "Urogenital Neoplasms", "Urologic Neoplasms", "Urologic Cancer", "Malignant Tumor of the Urinary Bladder", "Cancer of the Bladder" ], "interventions": [ { "name": "NanoDoce (direct injection)", "type": "DRUG" }, { "name": "NanoDoce (intravesical instillation) - Visit 2 Instillation", "type": "DRUG" }, { "name": "Institutional Standard of Care", "type": "OTHER" }, { "name": "NanoDoce (intravesical instillation) - Induction and Maintenance Instillations", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NanOlogy, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2019-04-02", "completion_date": "2021-11-02", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-10-09T07:28:33.890Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Baltimore, Maryland • New York, New York + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Myrtle Beach", "state": "South Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03636256" }, { "nct_id": "NCT04453293", "title": "Immunization With BCG Vaccine to Prevent Tuberculosis Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tuberculosis Infection" ], "interventions": [ { "name": "BCG (Tokyo 172) vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Henry M. Jackson Foundation for the Advancement of Military Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 16, "start_date": "2021-12-01", "completion_date": "2026-01-16", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-10-09T07:28:33.890Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Washington D.C., District of Columbia • Decatur, Georgia + 4 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04453293" }, { "nct_id": "NCT03317158", "title": "Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Bladder Cancer" ], "interventions": [ { "name": "Durvalumab (Cohort 1-3)", "type": "DRUG" }, { "name": "External Beam Radiotherapy (EBRT)", "type": "RADIATION" }, { "name": "Bacillus Calmette-Guérin (BCG)", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" }, { "name": "Durvalumab (Cohort 4/5)", "type": "DRUG" }, { "name": "To be determined", "type": "OTHER" }, { "name": "Intravesical NAI (Cohorts 6-7)", "type": "DRUG" }, { "name": "Subcutaneous NAI (Cohort 8)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL", "OTHER" ], "sponsor": "Noah Hahn, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2017-11-21", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-09T07:28:33.890Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Indianapolis, Indiana • Iowa City, Iowa + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03317158" }, { "nct_id": "NCT03582085", "title": "Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fibromyalgia" ], "interventions": [ { "name": "Bacillus Calmette Guerin Vaccine", "type": "BIOLOGICAL" }, { "name": "Saline Injection", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2026-01-01", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-10-09T07:28:33.890Z", "location_count": 1, "location_summary": "Charlestown, Massachusetts", "locations": [ { "city": "Charlestown", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03582085" }, { "nct_id": "NCT04640623", "title": "A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "TAR-200", "type": "DRUG" }, { "name": "Cetrelimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2020-12-18", "completion_date": "2027-09-30", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-09T07:28:33.890Z", "location_count": 22, "location_summary": "Tucson, Arizona • Los Angeles, California • Sherman Oaks, California + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sherman Oaks", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Golden", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04640623" }, { "nct_id": "NCT00003279", "title": "Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "BCG vaccine", "type": "BIOLOGICAL" }, { "name": "monoclonal antibody BEC2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "European Organisation for Research and Treatment of Cancer - EORTC", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "1998-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-03-06", "last_synced_at": "2026-10-09T07:28:33.890Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003279" }, { "nct_id": "NCT04179162", "title": "Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Muscle Invasive Bladder Cancer (NMIBC)" ], "interventions": [ { "name": "Bacillus Calmette-Guérin (BCG)", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2019-11-22", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-09T07:28:33.890Z", "location_count": 8, "location_summary": "Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04179162" }, { "nct_id": "NCT07222488", "title": "A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer", "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "MK-3120", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2025-12-09", "completion_date": "2029-02-28", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-09T07:28:33.890Z", "location_count": 4, "location_summary": "Bakersfield, California • New Brunswick, New Jersey • Myrtle Beach, South Carolina + 1 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Myrtle Beach", "state": "South Carolina" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07222488" } ] }